Junlin Ho Sells 5,742 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 5,742 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $211,477.86. Following the transaction, the general counsel now directly owns 189,295 shares of the company’s stock, valued at $6,971,734.85. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Junlin Ho also recently made the following trade(s):

• On Thursday, January 16th, Junlin Ho sold 9,039 shares of Scholar Rock stock. The stock was sold at an average price of $44.20, for a total value of $399,523.80.

Scholar Rock Stock Down 3.7 %

Shares of SRRK stock opened at $37.70 on Friday. The stock has a fifty day moving average price of $41.81 and a 200 day moving average price of $28.37. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Creative Planning acquired a new stake in Scholar Rock in the 3rd quarter valued at about $115,000. E. Ohman J or Asset Management AB grew its position in shares of Scholar Rock by 32.6% in the third quarter. E. Ohman J or Asset Management AB now owns 122,000 shares of the company’s stock valued at $977,000 after purchasing an additional 30,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock worth $25,000 after purchasing an additional 514 shares in the last quarter. abrdn plc raised its position in shares of Scholar Rock by 28.2% during the 3rd quarter. abrdn plc now owns 748,489 shares of the company’s stock worth $5,995,000 after purchasing an additional 164,715 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Scholar Rock by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,393 shares of the company’s stock worth $123,000 after purchasing an additional 6,023 shares during the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SRRK. HC Wainwright lifted their price target on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Wedbush reissued an “outperform” rating and issued a $47.00 target price on shares of Scholar Rock in a report on Wednesday, January 29th. Finally, Truist Financial upped their price target on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Scholar Rock currently has an average rating of “Buy” and a consensus price target of $40.43.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.